OBJECTIVES: The European Clinical Database EuCliD small star, filled has been developed as a tool for supervising selected quality indicators of about 200 European dialysis centers. Major efforts had to be made to comply with local and European laws regarding data security. METHOD: EuCliD is a Lotus Notes based flat-file database currently containing medical data of more than 14,000 dialysis patients from 10 European countries. Another 15,000 patients from 150 centers in 4 South-American countries will be added soon. Data are entered either manually or by means of interfaces to existing local data managing systems. This information is transferred to a central Lotus Notes Server. Data evaluation was performed with statistical tools like SPSS. RESULTS: EuCliD is used as a part of the CQI (Continuous Quality Improvement) management system of Fresenius Medical Care (FMC) dialysis units. Each participating dialysis center receives (currently every half year) benchmarking reports at a regular interval. The benchmark for all quality parameters is the weighted mean of the corresponding data of all centers. CONCLUSIONS: An obvious impact of data sampling and data evaluation on the quality of the treatments could be observed within the first one and a half years of working with EuCliD. This also concerns important outcome predictors like Kt/V and hemoglobin concentration as the outcome itself expressed in hospitalization days and survival rates. With the help of EuCliD the user is able to sample clinical data, identify problems, search for solutions with the aim of improving the dialysis treatment quality and guarantee a high-class treatment quality for all patients.
OBJECTIVES: The European Clinical Database EuCliD small star, filled has been developed as a tool for supervising selected quality indicators of about 200 European dialysis centers. Major efforts had to be made to comply with local and European laws regarding data security. METHOD: EuCliD is a Lotus Notes based flat-file database currently containing medical data of more than 14,000 dialysis patients from 10 European countries. Another 15,000 patients from 150 centers in 4 South-American countries will be added soon. Data are entered either manually or by means of interfaces to existing local data managing systems. This information is transferred to a central Lotus Notes Server. Data evaluation was performed with statistical tools like SPSS. RESULTS: EuCliD is used as a part of the CQI (Continuous Quality Improvement) management system of Fresenius Medical Care (FMC) dialysis units. Each participating dialysis center receives (currently every half year) benchmarking reports at a regular interval. The benchmark for all quality parameters is the weighted mean of the corresponding data of all centers. CONCLUSIONS: An obvious impact of data sampling and data evaluation on the quality of the treatments could be observed within the first one and a half years of working with EuCliD. This also concerns important outcome predictors like Kt/V and hemoglobin concentration as the outcome itself expressed in hospitalization days and survival rates. With the help of EuCliD the user is able to sample clinical data, identify problems, search for solutions with the aim of improving the dialysis treatment quality and guarantee a high-class treatment quality for all patients.
Authors: Isabella Cattinelli; Elena Bolzoni; Carlo Barbieri; Flavio Mari; José David Martin-Guerrero; Emilio Soria-Olivas; José Maria Martinez-Martinez; Juan Gomez-Sanchis; Claudia Amato; Andrea Stopper; Emanuele Gatti Journal: Health Care Manag Sci Date: 2011-11-15
Authors: Peter Stenvinkel; Iain A Gillespie; Jamie Tunks; Janet Addison; Florian Kronenberg; Tilman B Drueke; Daniele Marcelli; Guntram Schernthaner; Kai-Uwe Eckardt; Jürgen Floege; Marc Froissart; Stefan D Anker Journal: J Am Soc Nephrol Date: 2015-11-13 Impact factor: 10.121
Authors: Iain A Gillespie; Jürgen Floege; Ioanna Gioni; Tilman B Drüeke; Angel L de Francisco; Stefan D Anker; Yumi Kubo; David C Wheeler; Marc Froissart Journal: Pharmacoepidemiol Drug Saf Date: 2015-05-26 Impact factor: 2.890
Authors: Angel L M de Francisco; Javier Varas; Rosa Ramos; Jose Ignacio Merello; Bernard Canaud; Stefano Stuard; Julio Pascual; Pedro Aljama Journal: Kidney Int Rep Date: 2017-11-10
Authors: James Fotheringham; Michael T Smith; Marc Froissart; Florian Kronenberg; Peter Stenvinkel; Jürgen Floege; Kai-Uwe Eckardt; David C Wheeler Journal: BMC Nephrol Date: 2020-06-09 Impact factor: 2.388
Authors: James Fotheringham; Nicholas Latimer; Marc Froissart; Florian Kronenberg; Peter Stenvinkel; Jürgen Floege; Kai-Uwe Eckardt; David C Wheeler Journal: Clin Kidney J Date: 2020-12-28